Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612857 · ClinicalTrials.gov registry record · Phase 2
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2 study, sponsored by Idera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02612857 is a Phase 2 study that has completed, run by Idera Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT02612857, a Phase 2 study, has completed, sponsored by Idera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.
Interventions
- DRUG Placebo
- DRUG IMO-8400 Dose Group 1
- DRUG IMO-8400 Dose Group 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02612857
The ClinicalTrials.gov registry entry for NCT02612857 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idera Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02612857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02612857 about?
NCT02612857 is a clinical study titled "Trial of IMO-8400 in Adult Patients With Dermatomyositis". The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.
What is the current status of trial NCT02612857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2015-11. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02612857?
The interventions under investigation include: Placebo (DRUG), IMO-8400 Dose Group 1 (DRUG), IMO-8400 Dose Group 2 (DRUG).
Who is sponsoring clinical trial NCT02612857?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.